Safety Recommendations for Administering Intravenous Prostacyclins in the Hospital
Martha S. Kingman, DNP, FNP-C; Kelly Chin, MD
Safety Recommendations for Administering Intravenous Prostacyclins in the Hospital: Read Article
Get CE

Learning Objectives

At the completion of this program, you will be able to:
  • Distinguish between adverse effects of prostacyclins and symptoms of pulmonary artery hypertension
  • Summarize 4 approaches to prevent errors associated with high-risk medications
  • Describe 3 safety recommendations that reduce error during prostacyclin administration

Continuing Education Information

CE ID: C1352
Total Contact Hours: 1.00
Pharma Hours: 0.0
Synergy Cat: A
Test Expires: 10/1/2017


Prostacyclins are a high-risk category of continuous intravenous infusions increasingly used in hospitals to treat advanced pulmonary arterial hypertension, a rare condition characterized by vasoconstriction and vascular proliferation of the pulmonary arteries. Prostacyclins are given in doses of nanograms per kilogram per minute and have a narrow therapeutic dosing range for each patient. Sudden increases or decreases in dose can be life threatening. Previous studies revealed errors in the administration of these high-risk infusions, which in some instances led to serious adverse events, including death. We reviewed the literature for safety measures in administration of high-risk intravenous medications and obtained input from leading experts in pulmonary arterial hypertension to create

Publication/Sponsor Information

Critical Care Nurse is an official publication of the American Association of Critical-Care Nurses (AACN), and copyright belongs to AACN. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage retrieval system without permission of AACN. For all permission requests, please contact the Copyright Clearance Center, Customer Service, 222 Rosewood Drive, Danvers, MA 01923. (978) 750-8400. The statements and opinions contained herein are solely those of individual contributors and not of the editors, AACN, or The InnoVision Group. The editors, AACN, and The InnoVision Group assume that articles emanating from a particular institution are submitted with the approval of the requisite authority, including all matters pertaining to human studies and patient privacy requirements.

You have currently started taking the test for . To continue your test in progress, select Return to Test. To abandon this test select Cancel.

Your Feedback